triveni.bioHealthcare / BioTech & PharmaFounded: 2019Funding to Date: $232.24MM
Triveni Bio is a biotechnology company which offers genetics-informed precision medicine solutions to pharmaceutical companies and healthcare providers. Their proprietary platform is designed to identify and derisk novel therapeutic targets with strong genetic rationale across immunological and inflammatory disorders. By leveraging genetics with the goal of predicting and stratifying patient subpopulations, Triveni Bio aims to develop functional antibodies and provide insights into disease mechanisms. This company was founded by Tillman Gerngross Ph.D and Leonard Zon MD in 2019 and is headquartered in Watertown, MA.
Funding Date | Share Class | Amount Raised | Price per Share | Post-Money Valuation | Key Investors | |
---|---|---|---|---|---|---|
10/02/2024 | Series B | $115MM | $xx.xx | $310.4MM | Goldman Sachs, Fidelity, Deep Track Capital, Atlas Venture, Cormorant Asset Management, OrbiMed, Viking Global Investors, Invus | |
Price per Share
$xx.xx
Shares Outstanding
109,900,602
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
N/A
Key Investors
Goldman Sachs, Fidelity, Deep Track Capital, Atlas Venture, Cormorant Asset Management, OrbiMed, Viking Global Investors, Invus
|
||||||
10/26/2023 | Series A-2 | $7.5MM | $xx.xx | $150.45MM | Atlas Venture, Cormorant Asset Management, OrbiMed, Viking Global Investors, Invus, Polaris Partners, Alexandria Venture Investments | |
Price per Share
$xx.xx
Shares Outstanding
11,647,770
Liquidation Pref Order
2
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
N/A
Key Investors
Atlas Venture, Cormorant Asset Management, OrbiMed, Viking Global Investors, Invus, Polaris Partners, Alexandria Venture Investments
|
||||||
10/26/2023 | Series A-1 | $84.06MM | $xx.xx | $150.45MM | Atlas Venture, Cormorant Asset Management, OrbiMed, Viking Global Investors, Invus, Polaris Partners, Alexandria Venture Investments | |
Price per Share
$xx.xx
Shares Outstanding
104,439,376
Liquidation Pref Order
2
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
N/A
Key Investors
Atlas Venture, Cormorant Asset Management, OrbiMed, Viking Global Investors, Invus, Polaris Partners, Alexandria Venture Investments
|
||||||
10/15/2021 | Series Seed-3 | $15.28MM | $xx.xx | $106.17MM | Undisclosed Investors | |
Price per Share
$xx.xx
Shares Outstanding
7,074,786
Liquidation Pref Order
2
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
N/A
Key Investors
Undisclosed Investors
|
||||||
10/15/2021 | Series Seed-2 | $10MM | $xx.xx | $106.17MM | Undisclosed Investors | |
Price per Share
$xx.xx
Shares Outstanding
6,676,725
Liquidation Pref Order
2
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
N/A
Key Investors
Undisclosed Investors
|
||||||
10/15/2021 | Series Seed-1 | $400,000 | $xx.xx | $106.17MM | Undisclosed Investors | |
Price per Share
$xx.xx
Shares Outstanding
1,000,000
Liquidation Pref Order
2
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
N/A
Key Investors
Undisclosed Investors
|